-
-
-
-
-
-
-
RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on
-
-
-
-
-
-
-
RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights
-
-
-
-
-
-
-
RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights
-
-
-
-
-
-
-
RenovoRx (RNXT) Presenting Phase III Clinical Trial Interim Analysis Data
-
-
-
-
-
-
-
RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone
-
-
-
-
-
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

